

(FILE 'USPAT' ENTERED AT 15:26:06 ON 12 APR 1999)

L1 84 S ENTERAL (2W) (NUTRIT? OR ALIMENT? OR SUPPORT) (4W) (PROD  
UCT  
L2 107053 S LIPID OR FATTY? OR TRIGLYCERIDE  
E POLYSACCHARIDE  
L3 26574 S E3 OR CARBOHYDRATE  
L4 79119 S PROTEIN OR POLYPEPTIDE OR POLY PEPTIDE OR PEPTIDE  
L5 91487 S L4 OR AMINO ACIDS  
L6 6749 S L2 AND L3 AND L5  
L7 25518 S (VIT C OR VITAMIN C OR ASCORB?)  
L8 437 S L7 AND TAURINE  
L9 8000 S L7 AND ZINC  
L10 2774 S L9 AND (SE OR SELENIUM)  
L11 82 S L10 AND (CARNITI?)  
L12 112 S L10 AND L8  
L13 62 S L11 AND L8  
L14 54 S L13 AND L6  
L15 18 S L1 AND L14

=> d ab 1-18

US PAT NO: 5,780,451 [IMAGE AVAILABLE] L15: 1 of 18

ABSTRACT:

An **enteral nutritional product** for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible **carbohydrate** which is metabolized to short chain **fatty** acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

US PAT NO: 5,776,887 [IMAGE AVAILABLE] L15: 2 of 18

ABSTRACT:

Nutritional composition for use by diabetics containing a controlled absorbed **carbohydrate** component. The **carbohydrate** component contains a rapidly absorbed fraction such as glucose or sucrose, a moderately absorbed fraction such as certain cooked starches or fructose, and a slowly absorbed fraction such as raw corn starch.

US PAT NO: 5,763,392 [IMAGE AVAILABLE] L15: 3 of 18

ABSTRACT:

Method for lowering the plasma glucose levels of diabetics by administering myo-inositol. Also the invention concerns a nutritional composition containing myo-inositol.

US PAT NO: 5,714,472 [IMAGE AVAILABLE] L15: 4 of 18

ABSTRACT:

The present invention provides an **enteral nutritional formulation** that meets the nutrient requirements of intensive care patients who may have compromised absorption capacity. The present invention meets the unique nutrient needs of the patient that are generated due to tissue repair and healing requirements. To this end, in an embodiment the present invention provides a method for providing

nutritional support to intensive care patients comprising the steps of administering a therapeutically effective amount of a composition comprising: a **protein** source; a **carbohydrate** source; and a **lipid** source including a source of medium chain triglycerides, a source of omega-3 **fatty** acids, and a source of omega-6 **fatty** acids.

US PAT NO: 5,700,782 [IMAGE AVAILABLE]

L15: 5 of 18

ABSTRACT:

A liquid **enteral nutritional product** has been **formulated** which has utility, for example, for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy. The nutritional product is characterized by a **fatty** acid profile wherein, by weight: (a) the ratio of the sum of the n-3 to n-6 **fatty** acids is in the range of 1.37 to 1.70; (b) Eicosapentaenoic Acid (23:6n-3) is about 2.7-3.0% of total **fatty** acids.; and (c) Docosahexaenoic Acid (22:6n-3) is about 1.3-1.4% of total **fatty** acids. Preferably the nutritional product also contains intact **protein**, .beta.-carotene, **carnitine** and **taurine**.

US PAT NO: 5,661,123 [IMAGE AVAILABLE]

L15: 6 of 18

ABSTRACT:

The present invention provides a method for providing nutrition to non-catabolic and moderately catabolic patients. Pursuant to the present invention, the enteral composition includes a **peptide** based **protein** source of hydrolyzed whey, a **lipid** source, and a **carbohydrate** source. Preferably, the **protein** source includes approximately 22% to about 27% of the total calories. The composition has a caloric density of approximately 1000 Kcal/L and a low osmolality of approximately 300 to 450 mOsm/Kg H.sub.2O. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.

US PAT NO: 5,660,842 [IMAGE AVAILABLE]

L15: 7 of 18

ABSTRACT:

The present invention is directed to a method for inhibiting Helicobacter by administering C.sub.8 -C.sub.16 monoglycerides of **fatty** acids or lauric acid. The monoglycerides and/or lauric acid are conveniently administered via a nutritional composition.

US PAT NO: 5,547,927 [IMAGE AVAILABLE]

L15: 8 of 18

ABSTRACT:

An **enteral nutritional product** has been **formulated** for persons who are currently undergoing radiation therapy and/or chemotherapy. The nutritional product has a **protein** system which includes a soy **protein** hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 **fatty** acids that is in the range of about 1.3:1 to 2.5:1.

US PAT NO: 5,514,656 [IMAGE AVAILABLE]

L15: 9 of 18

ABSTRACT:

A method of providing enteral nutritional support to a person who is currently undergoing chemotherapy and/or radiation therapy involves including in the person's diet an **enteral nutritional product** having a **protein** system which includes a soy **protein** hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 **fatty** acids that is in the range of about 1.3:1 to 2.5:1.

US PAT NO: 5,480,872 [IMAGE AVAILABLE]

L15: 10 of 18

ABSTRACT:

Enteral nutritional support for a person infected with human immunodeficiency virus is provided by including in the diet a nutritional product which contains a soy **protein** hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact **protein**. The nutritional product has a ratio, by weight, of n-6 to n-3 **fatty** acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.

US PAT NO: 5,472,952 [IMAGE AVAILABLE]

L15: 11 of 18

ABSTRACT:

The present invention concerns nutritionally complete food compositions which contain partially hydrolyzed pectin. The partially hydrolyzed pectin has a peak molecular weight less than unmodified pectin and greater than 3,300.

US PAT NO: 5,444,054 [IMAGE AVAILABLE]

L15: 12 of 18

ABSTRACT:

A method of improving the nutritional status and reversing the characteristic diarrhea and inflammatory condition in a mammalian creature having ulcerative colitis or inflammation of the colon which contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible **carbohydrate** which is metabolized to short chain **fatty** acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

US PAT NO: 5,403,826 [IMAGE AVAILABLE]

L15: 13 of 18

ABSTRACT:

An **enteral nutritional product** for persons infected with human immunodeficiency virus contains a soy **protein** hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact **protein**. The nutritional product has a ratio, by weight, of n-6 to n-3 **fatty** acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.

US PAT NO: 5,340,603 [IMAGE AVAILABLE]

L15: 14 of 18

ABSTRACT:

A hypercaloric formula providing nutritional support for human infants having chronic lung disease, said formula having a caloric density of at least 800 kcalories per liter of formula and wherein not less than 56% of the total calories in said formula is derived from fat; not more than 15% of total calories is derived from a high quality **protein** source; and from about 20-27% of total calories is from a **carbohydrate** source; said formula having a calcium to phosphorous ratio in the range of 1.4 to 2.2, and having an m-inositol concentration of at least 50 milligrams per liter of formula.

US PAT NO: 5,330,972 [IMAGE AVAILABLE]

L15: 15 of 18

ABSTRACT:

The apoptosis of CD4 cells in a person infected with the human immunodeficiency virus may be impeded by enterally feeding to the

infected person a nutritional product which contains soy **protein** hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30%-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact **protein**. The nutritional product has a ratio, by weight, of n-6 to n-3 **fatty** acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.

US PAT NO: 5,308,832 [IMAGE AVAILABLE]

L15: 16 of 18

ABSTRACT:

An **enteral nutritional product** for a person having a neurological injury is very low in **carbohydrate**, but high in fat. The fat is supplied by a **lipid** blend having a ratio of n-6 to n-3 **fatty** acids in the range of 1 to 6. Preferably the nutritional product contains nutrients having antioxidant properties, for example beta-carotene, vitamin E, **vitamin C**, **taurine**, molybdenum and **selenium**.

US PAT NO: 5,223,285 [IMAGE AVAILABLE]

L15: 17 of 18

ABSTRACT:

A liquid nutritional product for enteral feeding contains a fat source which provides desirable effects when fed to pulmonary patients. The fat source having by weight a ratio of [n-(6) to n-(3)] **fatty** acids from the group consisting of Linoleic acid (18:2n6), Gamma-Linolenic acid (18:3n6), and Arachidonic acid (20:4n6) to **fatty** acids from the group consisting of Alpha-Linolenic acid (18:3n3), Stearidonic acid (18:4n3), Eicosapentaenoic acid (20:5n3), Docosapentaenoic acid (22:5n3) and Docosahexaenoic acid (22:6n3) in the range of about 1.5 to about 3.0, a ratio of Linoleic acid (18:2n6) to Alpha-Linolenic acid (18:3n3) in the range of about 3.0 to about 10.0, and a ratio of the sum of Eicosapentaenoic acid (20:5n3) and Docosahexaenoic acid (22:6n3) to Gamma-Linolenic acid (18:3n6) in the range of about 1.0 to about 10.0. In a preferred embodiment the nutritional product contains quantities of nutrients having anti-oxidant properties in vivo, such as beta-carotene, vitamin E, **vitamin C**, **selenium**, and **taurine**.

US PAT NO: 4,921,877 [IMAGE AVAILABLE]

L15: 18 of 18

ABSTRACT:

An improved nutritionally complete formula containing a unique fiber-containing **carbohydrate** blend, at a relatively low concentration; a unique fat blend, at a relatively high concentration; **protein**; **carnitine**; myoinositol; vitamins and minerals, including chromium. This formula is for the dietary management of patients with glucose intolerance.

> e mark david

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	1	MARJUS/BI
E2	USPAT	89431	MARK/BI
E3	USPAT	0 -->	MARK DAVID/BI
E4	USPAT	1	MARK0/BI
E5	USPAT	1	MARK0=1/BI
E6	USPAT	10	MARK1/BI
E7	USPAT	1	MARK11/BI
E8	USPAT	1	MARK1=1/BI
E9	USPAT	5	MARK2/BI
E10	USPAT	1	MARK207/BI
E11	USPAT	1	MARK21A/BI
E12	USPAT	2	MARK2B/BI

=> s mark, david/in

L1 5 MARK, DAVID/IN

=> e mark

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	2	MARJU/BI
E2	USPAT	1	MARJUS/BI
E3	USPAT	89431 -->	MARK/BI
E4	USPAT	1	MARK0/BI
E5	USPAT	1	MARK0=1/BI
E6	USPAT	10	MARK1/BI
E7	USPAT	1	MARK11/BI
E8	USPAT	1	MARK1=1/BI
E9	USPAT	5	MARK2/BI
E10	USPAT	1	MARK207/BI
E11	USPAT	1	MARK21A/BI
E12	USPAT	2	MARK2B/BI

=> e mark/in

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	1	MARJORAN, MICHAEL J/IN
E2	USPAT	4	MARJUSCHENKO, VILEN FEDOROVICH/IN
E3	USPAT	0 -->	MARK/IN
E4	USPAT	1	MARK, ABRAHAM S/IN
E5	USPAT	2	MARK, ALBERT/IN
E6	USPAT	2	MARK, ALEXANDER/IN
E7	USPAT	1	MARK, ALEXANDER D/IN
E8	USPAT	1	MARK, ALEXANDER H/IN
E9	USPAT	2	MARK, ALFRED J/IN
E10	USPAT	8	MARK, ANDRE/IN
E11	USPAT	8	MARK, ANDREW/IN
E12	USPAT	5	MARK, ANDREW R/IN

=> e

E13	USPAT	1	MARK, ANTONY ASHWELL/IN
E14	USPAT	2	MARK, ARNOLD/IN

E15	USPAT	1	MARK, ARTHUR M/IN
E16	USPAT	1	MARK, BY CAROL M REPRESENTATIVE/IN
E17	USPAT	1	MARK, BY ESTER H LEGAL REPRESENTATIVE/I N
E18	USPAT	1	MARK, BY ESTER H LEGAL REPRESENTATIVE/IN
E19	USPAT	1	MARK, BY ESTER H REPRESENTATIVE/IN
E20	USPAT	1	MARK, CAROL A/IN
E21	USPAT	1	MARK, CAROL M LEGAL REPRESENTATIVE/IN
E22	USPAT	2	MARK, CHARLES H/IN
E23	USPAT	1	MARK, DAMON/IN
E24	USPAT	111	MARK, DARREN M/IN

=> e

E25	USPAT	5	MARK, DAVID/IN
E26	USPAT	10	MARK, DAVID A/IN
E27	USPAT	20	MARK, DAVID F/IN
E28	USPAT	2	MARK, DAVID S/IN
E29	USPAT	3	MARK, DOUGLAS E/IN
E30	USPAT	1	MARK, EBERHARD VON DER/IN
E31	USPAT	1	MARK, EDGAR/IN
E32	USPAT	1	MARK, EDI/IN
E33	USPAT	2	MARK, EDWARD F/IN
E34	USPAT	6	MARK, EDWARD H/IN
E35	USPAT	1	MARK, EINO A/IN
E36	USPAT	3	MARK, ESTER H LEGAL REPRESENTATIVE/IN

=> s e25 and e26

	5 "MARK, DAVID"/IN
	10 "MARK, DAVID A"/IN
L2	0 "MARK, DAVID"/IN AND "MARK, DAVID A"/IN

=> s e25 or e26

	5 "MARK, DAVID"/IN
	10 "MARK, DAVID A"/IN
L3	15 "MARK, DAVID"/IN OR "MARK, DAVID A"/IN

=> dis 1-15

1. 5,766,621, Jun. 16, 1998, Support of pediatric patients; Susan Trimbo, et al., 424/439; 514/2, 21 [IMAGE AVAILABLE]
2. 5,747,459, May 5, 1998, Method for insuring adequate intracellular glutathione in tissue; W. Bruce Rowe, et al., 514/18; 530/331 [IMAGE AVAILABLE]
3. 5,733,884, Mar. 31, 1998, Enteral formulation designed for optimized wound healing; Adrian Barbul, et al., 514/21; 424/439; 426/72, 607, 656, 658; 514/2, 23, 54, 558, 560, 565, 943 [IMAGE AVAILABLE]
4. 5,723,446, Mar. 3, 1998, Enteral formulation designed for optimized nutrient absorption and wound healing; Debora Gray, et al., 514/21; 424/DIG.13; 426/72, 607, 656, 658; 514/2, 23, 54, 538, 560, 943 [IMAGE AVAILABLE]
5. 5,714,472, Feb. 3, 1998, Enteral formulation designed for optimized nutrient absorption and wound healing; Debora Gray, et al., 514/21; 424/DIG.13; 426/72, 607, 656, 658; 514/2, 23, 54, 558, 560, 943 [IMAGE AVAILABLE]
6. 5,635,199, Jun. 3, 1997, Support of pediatric patients; Susan Trimbo, et al., 424/439; 514/2, 21 [IMAGE AVAILABLE]

7. 5,549,905, Aug. 27, 1996, Enteral composition for pediatric patients; **David A. Mark**, et al., 424/439; 514/23 [IMAGE AVAILABLE]
8. 5,378,722, Jan. 3, 1995, Nutritional compositions for management of nitrogen metabolism; David C. Madsen, et al., 514/410 [IMAGE AVAILABLE]
9. 5,356,873, Oct. 18, 1994, Method for providing nutritional requirements to patients having a chronic inflammation reaction; **David A. Mark**, et al., 514/2; 426/2; 514/561, 565 [IMAGE AVAILABLE]
10. 5,229,136, Jul. 20, 1993, Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients; **David A. Mark**, et al., 424/535, 195.1; 426/72, 583, 804 [IMAGE AVAILABLE]
11. 5,214,062, May 25, 1993, Method and composition for treating immune disorders, inflammation and chronic infections; **David A. Mark**, et al., 514/369, 18, 560 [IMAGE AVAILABLE]
12. 4,740,220, Apr. 26, 1988, Dust detection; **David Mark**, et al., 73/863.22; 55/325, 332, 439, 446 [IMAGE AVAILABLE]
13. 4,675,034, Jun. 23, 1987, Dust collector; Gordon Lynch, et al., 73/863.23; 55/504 [IMAGE AVAILABLE]
14. 4,616,513, Oct. 14, 1986, Dust collection; Harold Gibson, et al., 73/863.23 [IMAGE AVAILABLE]
15. 4,586,389, May 6, 1986, Dust detection; James H. Vincent, et al., 73/863.22; 55/317, 403, 462, 524; 96/413 [IMAGE AVAILABLE]

=> e twyaman/in

E#	FILE	FREQUENCY	TERM
--	----	-----	-----
E1	USPAT	1	TWUBAKI, TOSHIO/IN
E2	USPAT	1	TWUMASI, DANIEL Y/IN
E3	USPAT	0 -->	TWYAMAN/IN
E4	USPAT	2	TWYDELL, ROLAND S/IN
E5	USPAT	1	TWYFORD, DAVID R/IN
E6	USPAT	1	TWYFORD, LEE V/IN
E7	USPAT	11	TWYFORD, ROBERT H/IN
E8	USPAT	2	TWYFORD, ROBERT H JR/IN
E9	USPAT	1	TWYMAN, BENJAMIN E/IN
E10	USPAT	3	TWYMAN, BILL I/IN
E11	USPAT	1	TWYMAN, CLIVE R/IN
E12	USPAT	6	TWYMAN, DIANA/IN

=> e twyman/in

E#	FILE	FREQUENCY	TERM
--	----	-----	-----
E1	USPAT	11	TWYFORD, ROBERT H/IN
E2	USPAT	2	TWYFORD, ROBERT H JR/IN
E3	USPAT	0 -->	TWYMAN/IN
E4	USPAT	1	TWYMAN, BENJAMIN E/IN
E5	USPAT	3	TWYMAN, BILL I/IN
E6	USPAT	1	TWYMAN, CLIVE R/IN
E7	USPAT	6	TWYMAN, DIANA/IN
E8	USPAT	2	TWYMAN, DIANA L/IN
E9	USPAT	1	TWYMAN, GUY L/IN
E10	USPAT	1	TWYMAN, HAROLD F/IN
E11	USPAT	3	TWYMAN, JEFFREY R/IN
E12	USPAT	2	TWYMAN, NANCY D/IN

=> s e7 or e8

```

        6 "TWYMAN, DIANA"/IN
        2 "TWYMAN, DIANA L"/IN
L4      8 "TWYMAN, DIANA"/IN OR "TWYMAN, DIANA L"/IN

```

=> d 1-8

1. 5,733,884, Mar. 31, 1998, Enteral formulation designed for optimized wound healing; Adrian Barbul, et al., 514/21; 424/439; 426/72, 607, 656, 658; 514/2, 23, 54, 558, 560, 565, 943 [IMAGE AVAILABLE]
2. 5,728,678, Mar. 17, 1998, Method and composition for providing nutrition to a renal failure patient; Susan Trimbo, et al., 514/12; 424/535; 426/583, 656, 657; 514/2, 561, 869, 943 [IMAGE AVAILABLE]
3. 5,723,446, Mar. 3, 1998, Enteral formulation designed for optimized nutrient absorption and wound healing; Debora Gray, et al., 514/21; 424/DIG.13; 426/72, 607, 656, 658; 514/2, 23, 54, 538, 560, 943 [IMAGE AVAILABLE]
4. 5,714,472, Feb. 3, 1998, Enteral formulation designed for optimized nutrient absorption and wound healing; Debora Gray, et al., 514/21; 424/DIG.13; 426/72, 607, 656, 658; 514/2, 23, 54, 558, 560, 943 [IMAGE AVAILABLE]
5. 5,661,123, Aug. 26, 1997, Enteral composition for malabsorbing patients; Lance Stalker, et al., 514/2, 23, 474, 547, 556, 560, 578, 643, 681, 702, 763 [IMAGE AVAILABLE]
6. 5,549,905, Aug. 27, 1996, Enteral composition for pediatric patients; David A. Mark, et al., 424/439; 514/23 [IMAGE AVAILABLE]
7. 4,880,014, Nov. 14, 1989, Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements; Barbara J. Zarowitz, et al., 600/547; 604/500 [IMAGE AVAILABLE]
8. 4,613,323, Sep. 23, 1986, Multiple function intubation apparatus and method; Jane A. Norton, et al., 604/43, 270, 514 [IMAGE AVAILABLE]

=> e michalski/in

E#	FILE	FREQUENCY	TERM
--	----	-----	----
E1	USPAT	2	MICHALSKE, TERRY A/IN
E2	USPAT	1	MICHALSKE, TERRY ARTHUR/IN
E3	USPAT	0 -->	MICHALSKI/IN
E4	USPAT	4	MICHALSKI, ARNOLD/IN
E5	USPAT	1	MICHALSKI, ARTUR/IN
E6	USPAT	3	MICHALSKI, BERNHARD/IN
E7	USPAT	1	MICHALSKI, BRITTA/IN
E8	USPAT	3	MICHALSKI, CATHERINE/IN
E9	USPAT	1	MICHALSKI, CHRIS A/IN
E10	USPAT	1	MICHALSKI, DANIEL G/IN
E11	USPAT	1	MICHALSKI, DANIEL T/IN
E12	USPAT	2	MICHALSKI, DAVID E/IN

=> e

E13	USPAT	5	MICHALSKI, DENNIS H/IN
E14	USPAT	9	MICHALSKI, DIETER/IN
E15	USPAT	2	MICHALSKI, GUNTER/IN
E16	USPAT	2	MICHALSKI, JAN/IN
E17	USPAT	2	MICHALSKI, JOHN D/IN